References
- Sehirli AO, Sener G, Ercan F. Protective effects of pycnogenol against ischemia-reperfusion induced oxidative renal injury in rats. Ren Fail. 2009;31:690–697
- Koo DD, Welsh KI, West NE, et al. Endothelial cell protection against ischemia/reperfusion injury by lecithinized superoxide dismutase. Kidney Int. 2001;60:786–796
- Anaya-Prado R, Toledo-Pereyra LH. The molecular events underlying ischemia-reperfusion injury. Transpl Proc. 2002;34:2518–2519
- Granger DN, Korthuis RJ. Physiological mechanisms of postischemic tissue injury. Annu Rev Physiol. 1995;57:311–332
- Ma D, Rajakumaraswamy N, Maze M. α2-Adrenoceptor agonists: Shedding light on neuroprotection? Br Med Bull. 2005;71:77–92
- Arcangeli A, Alo CD, Gaspari R. Dexmedetomidine use in general anaesthesia. Curr Drug Targets. 2009;10:687–695
- Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978;34:271–278
- Sun Y, Oberley L, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988;34:497–500
- Aebi H. Catalase methods of enzymatic analysis. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York: Academic Press; 1974;673–677
- Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;8:70–77
- Das DK, Maulik N. Antioxidant effectiveness in ischemia-reperfusion tissue injury. Methods Enzymol. 1994;233:601–610
- Ysebaert DK, De Greef KE, Vercauteren SR, et al. Identification and kinetics of leukocytes after severe ischemia/reperfusion renal injury. Nephrol Dial Transplant. 2000;15:1562–1574
- Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Hemost. 2007;97:738–747
- Thurman JM. Triggers of Inflammation after renal ischemia/reperfusion. Clin Immunol. 2007;123:7–13
- Suyani E, Derici UB, Sahin T, et al. Effects of everolimus on cytokines, oxidative stress and renal histology in ischemia-reperfusion injury of the kidney. Ren Fail. 2009;31:698–703
- Gu J, Chen J, Xia P, Tao G, Zhao H, Ma D. Dexmedetomidine attenuates remote lung injury induced by renal ischemia-reperfusion in mice. Acta Anaesthesiol Scand. 2011;55:1272–1278
- Sahin T, Begeç Z, Toprak Hİ, et al. The effects of dexmedetomidine on liver ischemia-reperfusion injury in rats. J Surg Res. 2013;183:385–390
- Sugita S, Okabe T, Sakamoto A. Continuous infusion of dexmedetomidine improves renal ischemia-reperfusion injury in rat kidney. J Nippon Med Sch. 2013;80:131–139
- Si Y, Bao H, Han L, et al. Dexmedetomidine protect against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activation. J Transl Med. 2013;141:9–11
- Lameire NH, Vanholder R. Pathophysiology of ischemic acute renal failure. Best Pract Res Clin Anaesthesiol. 2004;18:21–36
- Edelstein CL. Biomarkers of acute kidney injury. Adv Chronic Kidney Dis. 2008;15: 222–234
- Kocoglu H, Ozturk H, Ozturk H, Yilmaz F, Gulcu N. Effect of dexmedetomidine on ischemia-reperfusion injury in rat kidney: A histopathologic study. Ren Fail. 2009;31:70–74